Company: MDCXW
Filing Date: 2025-12-08
Form Type: 253G2
Source: 0001062993-25-017235
Chunk: 3

Company: Medicus Pharma Ltd.
Filing Date: 2025-12-08
Form: 253G2
Chunk 3
---
 addition, in certain circumstances, upon a fundamental transaction (as defined in the New Warrants), a holder of New Warrants will be entitled to receive, upon exercise of the New Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the New Warrants immediately prior to the fundamental transaction. Additionally, as more fully described in the New Warrants, in the event of certain fundamental transactions, the holders of the New Warrants will be entitled to receive consideration in an amount equal to the Black Scholes value of the New Warrants on the date of consummation of the transaction.

The closing is expected to take place on or about December 8, 2025, subject to satisfaction of customary closing conditions. Gross proceeds to the Company from the exercise of the Existing Warrants is expected to be approximately $5.1 million, prior to deducting any expenses and placement agent fees as further described below.

The Common Shares underlying the Existing Warrants are registered for resale under the Company's effective registration statement on Form S-1 (File No. 333-291651).

The Company has undertaken in the Agreement to file a registration statement on Form S-1 or Form S-3 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") providing for the resale of the New Warrant Shares as soon as practicable, and in any event within sixty (60) calendar days of the date of the Agreement (the "Initial Filing Date), and to use commercially reasonable efforts to have such Registration Statement declared effective by the SEC on or prior to the sixtieth (60) calendar day after the Initial Filing Date. Pursuant to the Agreement, the Company will use commercially reasonable efforts to keep such Registration Statement effective at all times until the original holder of the New Warrants may sell its New Warrant Shares without volume or manner of sale limitation under Rule 144.

In connection with the transactions contemplated in the Agreement, the Company agreed to pay its exclusive financial advisor, Maxim Group LLC, a cash fee equal to 6.0% of the gross proceeds received by the Company in the transactions contemplated by the Agreement.

The foregoing descriptions of the New Warrants and Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the New Warrants and the Agreement, forms of which are attached to this Current Report on Form 8-K as Exhibits 4.1 and 4.2, and 10